Impaired DNA damage response - An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 143-150

  Darzynkiewicz, Zbigniew ^a   Traganos, Frank ^a   Wlodkowic, Donald ^b,c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Cytotech Consultancy   (United Kingdom)

Author keywords

ATM; BRCA1; BRCA2; Chk1; Chk2; GammaH2AX

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; HISTONE H2AX; IMATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN TYROSINE PHOSPHATASE; SERINE; TYROSINE;

APOPTOSIS; ATAXIA TELANGIECTASIA; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMATIN CONDENSATION; CHRONIC MYELOID LEUKEMIA; CONFORMATIONAL TRANSITION; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; MISMATCH REPAIR; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SENESCENCE; XERODERMA PIGMENTOSUM;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 71749111299     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.05.032     Document Type: Review

References (140)

1. Abraham R.T., and Tibbetts R.S. Guiding ATM to broken DNA. Science 308 (2005) 510-511
2. Ahn J.Y., Schwartz J.K., Piwnica-Worms H., and Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60 (2000) 5934-5936
3. Ahn J.Y., Li X., Davis H.L., and Canman C.E. Phosphorylation of threonine 68 promotes ologomerization and autophosphorylation of Chk2 protein kinase via the forkhead-associated domain. J. Biol. Chem. 277 (2002) 19389-19395
4. Ahn J., Urist M., and Prives C. The Chk2 protein kinase. DNA Repair 3 (2004) 1039-1047
5. Albino A.P., Huang X., Yang J., Gietl D., Jorgensen E., Traganos F., and Darzynkiewicz Z. Induction of histone H2AX phosphorylation in A549 human pulmonary epithelial cells by tobacco smoke and in human bronchial epithelial cells by smoke condensate: a new assay to detect the presence of potential carcinogens in tobacco. Cell Cycle 3 (2004) 1062-1068
6. Albino A.P., Huang X., Jorgensen E., Gietl D., Traganos F., and Darzynkiewicz Z. Induction of DNA double-strand breaks in A549 and normal human pulmonary epithelial cells by cigarette smoke is mediated by free radicals. Int. J. Oncol. 28 (2006) 1491-1505
7. Amadori D., Volpi A., Maltoni R., Nanni O., Amaducci L., Amadori A., Giunchi D.C., Vio A., Saragoni A., and Silvestrini R. Cell proliferation as a predictor of a response to chemotherapy in metastatic breast cancer: a prospective study. Breast Canc. Res. Treat. 43 (2004) 7-14
8. Aressy B., Bugler B., Valette A., Biard D., and Ducommun B. Moderate variation in CDC25B protein levels modulate the response to DNA damaging agents. Cell Cycle 7 (2008) 2234-2240
9. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP)ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26 (2008) 3785-3790
10. Bakkenist C.J., and Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 (2003) 499-506
11. Bakkenist C.J., and Kastan M.B. Initiating cellular stress responses. Cell 118 (2004) 9-17
12. Bartkova J., Bakkenist C.J., Rajpert-De Meyts E., Skakkebaek N.E., Sehested M., Lukas J., Kastan M.B., and Bartek J. ATM activation in normal human tissues and testicular cancer. Cell Cycle 4 (2005) 838-845
13. Bartkova J., Rajpert-De Meyts E., Skakkebaek N.E., Lukas J., and Bartek J. DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy. Int. J. Androl. 30 (2007) 282-291
14. Biton S., Barzilay A., and Shiloh Y. The neurological phenotype of ataxia-telangiectasia: solving a persistent puzzle. DNA Repair 7 (2008) 1028-1038
15. Blagosklonny M.V. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int. J. Oncol. 19 (2001) 257-262
16. Blagosklonny M.V., and Darzynkiewicz Z. Cyclotherapy: protecting of normal cells and unshielding of cancer cells. Cell Cycle 1 (2002) 375-382
17. Blagosklonny M.V., and Pardee A.B. The restriction point of the cell cycle. Cell Cycle 1 (2002) 103-110
18. Bonner W.M., Redon C.E., Dickey J.S., Nakamura A.J., Sedelnikova O.A., Solier S., and Pommier Y. γH2AX and cancer. Nat. Rev. 8 (2008) 957-967
19. Borst P., Rottenberg S., and Jonkers J. How do real tumors become resistant to cisplatin?. Cell Cycle 7 (2008) 1353-1359
20. Boutros R., Dozier C., and Ducommun B. The when and wheres of CDC25 phosphatases. Curr. Opin. Cell Biol. 18 (2006) 185-191
21. Boutros R., Lobjois V., and Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat. Rev. Cancer 7 (2007) 495-507
22. Boyes B.E., Crean G.P., and Watkinson G. Studies in the rates of epithelial cell exfoliation from the gastric mucosa in normal and in ulcer subjects. Gut 12 (1971) 867-869
23. Braunschweiger P.G., and Schiffer L.M. Cell kinetic-directed sequential chemotherapy with cyclophosphamide and adriamycin in T1699 mammary tumors. Cancer Res. 40 (1980) 737-743
24. Braunschweiger P.G., Schenken L.L., and Schiffer L.M. The cytokinetic basis for the design of efficacious radiotherapy protocols. Int. J. Radiat. Oncol. Biol. Phys. 5 (1979) 37-47
25. Brezak M.C., Kasprzyk P.G., Galcera M.O., Lavergne O., and Prevost G.P. CDC25 inhibitors as anticancer agents are moving forward. Anticancer Agents Med. Chem. 8 (2008) 857-862
26. Brons P.P., Haanen C., Boezeman J.B., Muus P., Holdrinet R.R., Pennings A.H., Wessels H.M., and de Witte T. Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell kinetics. Ann. Hematol. 66 (1993) 225-233
27. Bruno S., Ardelt B., Skierski J.S., Traganos F., and Darzynkiewicz Z. Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res. 52 (1992) 470-473
28. Burma S., Chen B.P., Murphy M., Kurimasa A., and Chen D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 276 (2001) 42462-42467
29. Caldecott K.W., and Chalmers A. An Achilles' heel for breast cancer?. Nat. Struct. Mol. Biol. 12 (2005) 387-398
30. Cass I., Baldwin R.L., Varkey T., Moslehi R., Narod S.A., and Karlan B.Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97 (2003) 2187-2195
31. Celeste A., Paterson S., Romanienko P.J., Fernandez-Capetillo O., Chen H.T., Sedelnikova A., Reina-San M.B., Coppola V., Meffre E., Difilippantonio M.J., Redon C., Pilch D.R., Olaru A., Eckhaus M., Camerini-Otero R.D., Tessarollo L., Livak F., Manova K., Bonner W.M., Nussenzweig M.C., and Nussenzweig A. Genomic instability in mice lacking histone H2AX. Science 296 (2001) 922-927
32. Celeste A., Difilippantonio S., Fernandez-Capetillo O., Pilch D.R., Sedelnikova O., Eckhaus M., Ried T., Bonner W.M., and Nussenzweig A. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114 (2003) 371-383
33. Clarkson B., Ohkita T., Ota K., and Fried J. Studies of cellular proliferation in human leukemia. I. Estimation of growth rates of leukemic and normal hematopoietic cells in two adults with acute leukemia given a single injection of tritiated thymidine. J. Clin. Invest. 46 (1967) 506-525
34. Collins I., and Garrett M.D. Targeting the cell division cycle in cancer: CDK and the cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol. 5 (2005) 366-373
35. Cook P.J., Ju B.G., Telese F., Wang X., Glass C., and Rosenfeld M.G. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 458 (2009) 591-596
36. Cuadrado M., Martinez-Pastor B., and Fernandez-Capetillo O. ATR activation in response to ionizing radiation: still ATM territory. Cell Div. 1 (2006) 7. http://www.celldiv.com/content/1/1/7 http://www.celldiv.com/content/1/1/7
37. de Winter J.P., and Joenje H. The genetic and molecular basis of Fanconi anemia. Mutat. Res. 668 (2009) 11-19
38. Deep G., and Agarwal R. New combination therapies with cell cycle agents. Curr. Opin. Invest. Drugs 9 (2008) 591-604
39. Dergoglio V., and Magnaldo T. Nucleotide excision repair and related human diseases. Genome Dyn. 1 (2006) 35-52
40. Difilippantonio S., and Nussenzweig A. The NBS1-ATM connection revisited. Cell Cycle 6 (2007) 2366-2370
41. Ding J., Miao Z.H., Meng L.H., and Geng M.Y. Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol. Sci. 27 (2006) 338-344
42. Dobzhansky T. Genetics of natural populations: XIII. Recombination and variability of in populations of Drosophila Pseudoobscura. Genetics 31 (1946) 269-290
43. Dormer P., Hegemann F., and Brinkmann W. Proliferation and production of hemopoietic cells in two stages of disease: preleukemia and overt leukemia. Klin. Wochenschr 54 (1976) 461-466
44. Downs J.A., and Cote J. Dynamics of chromatin during the repair of DNA double-strand breaks. Cell Cycle 4 (2005) 1373-1376
45. Dziegielewski J., and Beerman T.A. Cellular responses to the DNA strand-scission eneidine C-1027 can be independent of ATM, ATR and DNA-PK kinases. J. Biol. Chem. 277 (2002) 20549-50554
46. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J. Cell. Biochem. 91 (2004) 223-231
47. Fackenthal J.D., and Olopade O.J. Brast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat. Rev. Cancer 7 (2007) 937-948
48. Garber K. New checkpoint blockers begin human trials. J. Natl. Canc. Inst. 97 (2005) 1026-1028
49. Halicka H.D., Huang X., Traganos F., King M.A., Dai W., and Darzynkiewicz Z. Histone H2AX phosphorylation after cell irradiation with UV-B: relationship to cell cycle phase and induction of apoptosis. Cell Cycle 4 (2005) 339-345
50. Halicka H.D., Ozkaynak M.F., Levendoglu-Tugal O., Sandoval C., Seiter K., Kajstura M., Traganos F., Jayabose S., and Darzynkiewicz Z. DNA damage response as a biomarker in treatment of leukemias. Cell Cycle 8 (2009) 1720-1724
51. Halicka H.D., Zhao H., Podhorecka M., Traganos F., and Darzynkiewicz Z. Cytometric detection of chromatin relaxation, an early reporter of DNA damage response. Cell Cycle 8 (2009) 2233-2237
52. Helleday T. Aplifying tumour-specific replication lesions by DNA repair inhibitors - a new era in targeted cancer therapy. Eur. J. Cancer 44 (2008) 921-927
53. Helt C.E., Cliby W.A., Keng P.C., Bambara R.A., and O'Reilly M.A. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J. Biol. Chem. 280 (2005) 1186-1192
54. Hickson I., Zhao Y., Richardson C.J., Green S.J., Martin N.M., Orr A.I., Reaper P.M., Jackson S.P., Curtin N.J., and Smith G.C. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64 (2004) 9152-9159
55. Hill B.T. Cancer chemotherapy. The relevance of certain concepts of cell cycle kinetics. Biochem. Biophys. Acta 516 (1975) 389-417
56. Hoogduijn M.J., Gorjup J., and Genever P.G. Comparative characterization of hair follicle dermal stem cells and bone marrow mesenchymal stem cells. Stem Cells Develop 15 (2006) 49-60
57. Hsieh P., and Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech. Ageing Dev. 129 (2008) 391-407
58. Huang X., Okafuji M., Traganos F., Luther E., Holden E., and Darzynkiewicz Z. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by DNA crosslinking agent cisplatin. Cytometry A 58A (2004) 99-110
59. Huang X., King M., Halicka D.H., Traganos F., Okafuji M., and Darzynkiewicz Z. Histone H2AX phosphorylation induced by selective photolysis of BrdU-labeled DNA with UV light: relationship to cell cycle phase. Cytometry A 62A (2004) 1-7
60. Ismail I.H., Nystrom S., Nygren J., and Hammersten O. Activation of ataxia telangiectasia mutated by DNA strand break-inducing agents correlates closely with the number of DNA double strand breaks. J. Biol. Chem. 280 (2005) 4649-4655
61. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5 (2005) 689-698
62. Karp J.E., and Burke P.J. Enhancement of drug cytotoxicity by recruitment of leukemic myeloblasts with humoral stimulation. Cancer Res. 36 (1976) 3600-3603
63. Kastan M.B. DNA damage responses: mechanisms and roles in human disease. 2007 G.H.A. Cloves Memorial Award Lecture. Mol. Cancer Res. 6 (2008) 517-524
64. Kastan M.B., and Lim D.S. The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 1 (2000) 179-186
65. Kennedy R.D., Quinn J.E., Mullan P.B., and Johnston P.G. The role of BRCA1 in the cellular response to chemotherapy. JNCI 96 (2004) 1659-1668
66. Kitagawa R., and Kastan M.B. The ATM-dependent DNA damage signaling pathway. Cold Spring Harbor Symp. Quant. Biol. 70 (2005) 99-109
67. Kitagawa R., Bakkenist C.J., McKinnon P.J., and Kastan M.B. Phosphorylation of SMC1 is a critical downstream event in the ATM-ANBS1-BRCA1 pathway. Genes Dev. 18 (2004) 1423-1438
68. Kremer W.B., Vogler W.R., and Chan Y.K. An attempt at synchronization of marrow cells in acute leukemia: relationship to therapeutic response. Cancer 37 (1976) 390-403
69. Kurose A., Tanaka T., Huang X., Traganos F., Dai W., and Darzynkiewicz Z. Effects of hydroxyurea and aphidicolin on phosphorylation of ATM on Ser 1981 and histone H2AX on Ser 139 in relation to cell cycle phase and induction of apoptosis. Cytometry A 69A (2006) 212-221
70. Kyle S., Thomas H.D., Mitchell J., and Curtin N.J. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer. Br. J. Radiol. 81 Spec. No. 1 (2008) S6-S11
71. Lavin M.F. Ataxia-telangiectasia: from a rare disorder to w paradigm for cell signaling and cancer. Nat. Rev. Mol. Cell Biol. 9 (2008) 759-769
72. Lee J.H., and Paull T.T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308 (2005) 551-554
73. Lee J.S., Collins K.M., Brown A.L., Lee C.H., and Chung J.H. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404 (2000) 201-204
74. Li J., and Stern D.F. DNA damage regulates Chk2 association with chromatin. J. Biol. Chem. 280 (2005) 37948-37956
75. Li L., and Zou L. Sensing signaling and responding to DNA damage: organization of checkpoint pathways in mammalian cells. J. Cell Biochem. 94 (2005) 298-306
76. Lieberman H.B. DNA damage repair and response proteins as targets for cancer therapy. Curr. Med. Chem. 15 (2008) 360-367
77. Lin J., Reichner C., Wu X., and Levine A.J. Analysis of wild-type and mutant p21WAF-1 gene activities. Mol. Cell Biol. 16 (1996) 1786-1793
78. Lipkin M. Proliferation and differentiation of gastrointestinal cells. Physiol. Rev. 53 (1973) 891-915
79. Lipkin M., Sherlock P., and Bell B. Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum. Gastroenterology 45 (1966) 721-729
80. Lord C.J., and Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8 (2008) 363-369
81. Lord C.J., Garrett M.D., and Ashworth A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin. Cancer Res. 12 (2006) 4463-4468
82. Lukas J., and Bartek J. New tales of an old tail. Nature 458 (2009) 581-583
83. MacPhail S.H., Banath J.P., Yu T.Y., Chu E.H., Lambur H., and Olive P.L. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int. J. Radiat. Biol. 79 (2003) 351-358
84. Madhusudan S., and Middleton M.R. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat. Rev. 31 (2005) 603-617
85. Martin S.A., Lord C.J., and Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr. Opin. Genet. Dev. 18 (2008) 80-86
86. Matsuoka S., Huang M., and Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282 (1998) 1893-1897
87. Matsuoka S., Rotman G., Ogawa A., Shiloh K., Tamai S.J., and Elledge S.J. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10289-10394
88. Mukherjee B., Kessinger C., Kabayashi J., Chen B.P., Chen D.J., Chatterjee A., and Burma S. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA Repair (Amst.) 10 (2006) 575-590
89. Muller B.A. Imatinib and its successors - how modern chemistry has changed drug development. Curr. Pharm. Des. 15 (2009) 120-133
90. Murga M., Jaco I., Soria R., Martinez-Pastor B., Cuadrado M., Yang S.-M., Blasco M.A., Skoultchi A.I., and Fernandez-Capetillo O. Global chromatin compaction limits the strength of the DNA damage response. J. Cell Biol. 178 (2007) 1101-1108
91. Nakamura A., Sedelnikova O.A., Redon C., Pilch D.R., Sinogeeva N.I., Shroff R., Lichten M., and Bonner W.M. Techniques for gamma-H2AX detection. Methods Enzymol. 409 (2006) 236-250
92. O'Connor M.J., Martin N.M., and Smith G.C. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 26 (2007) 7816-7824
93. Olive P.L. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol. 75 (2004) 355-373
94. Pal T., Permuth-Way J., Kapoor R., Cantor R., and Sutphen R. Improved survival in BRCA2 carriers with ovarian cancer. Fam. Cancer 6 (2007) 113-119
95. Pandita T.K., and Richardson C. Chromatin remodeling finds its place in the DNA double-strand breaks. Nucleic Acids Res. (2009) 1-15 (Advanced ePubl)
96. Pardee A.B. A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 71 (1974) 1286-1290
97. Pardee A.B., and James L.J. Selective killing of transformed baby hamster kidney (BHK) cells. Proc. Natl. Acad. Sci. U. S. A. 72 (1975) 4994-4998
98. Paull T.T., and Lee J.H. The Mre11/Rad50/Nbs1 complex and its role as a DNA-double strand break sensor for ATM. Cell Cycle 4 (2005) 737-740
99. Peng C.Y., Graves P.R., Thoma R.S., Wu Z., Shaw A.S., and Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277 (1997) 1501-1505
100. Pietrzak M., Halicka H.D., Wieczorek Z., Wieczorek J., and Darzynkiewicz Z. Attenuation of acridine mutagen ICR 191-DNA interactions and DNA damage by the mutagen interceptorchlorophyllin. Biophys. J. 135 (2008) 69-75
101. Powell S.N., and Kachnie L.A. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med. Chem. 8 (2008) 448-460
102. Quinn J.E., Carser J.E., James C.R., Kennedy R.D., and Harkin D.P. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol. Onc. 113 (2009) 134-142
103. Raitsema T., Klokov D., Banath J.P., and Olive P.L. DNA-PK is responsible for enhanced phosphorylation of histone H2AX under hypertonic conditions. DNA Repair (Amst.) 28 (2005) 1172-1181
104. Rogakou E.P., Nieves-Neira W., Boon C., Pommier Y., and Bonner W.M. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J. Biol. Chem. 275 (2000) 9390-9395
105. Rouleau M., Aubin R.A., and Poirier G.G. Poly(ADP-ribosyl)ated chromatin domains: access granted. J. Cell Sci. 117 (2004) 815-825
106. Rubbi C.P., and Milner J. p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. EMBO J. 22 (2003) 975-986
107. Rudolph J. Cdc25 phosphatases: structure, specificity and mechanism. Biochemistry 46 (2007) 3595-3604
108. Santarosa M., Del Col L., Tonin E., Caragnano A., Viel A., and Maestro R. Premature senescence is a major response to DNA cross-linking agents in BRCA-1 defective cells: implication for tailored treatments of BRCA1 mutation carriers. Mol. Cancer Ther. 8 (2009) 844-854
109. 125IUdr-induced DNA double-strand breaks with γ-H2AX antibody. Radiation Res. 158 (2002) 486-492
110. Seoane M., Iglesias P., Gonzalez T., Domininguez F., Fraga M., Aliste C., Forteza J., and Costoya J.A. Retinoblastoma loss modulates DNA damage response favoring tumor progression. PLoS ONE 3 (2008) e3632 (Electronic publication Nov5)
111. Shen S.X., Weaver Z., Xu X., Li C., Weinstein M., Chen L., Guan X.Y., Ried T., and Deng C.X. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 17 (1998) 3115-3124
112. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 22 (2003) 5834-5868
113. Smart D.J., Halicka H.D., Schmuck G., Traganos F., Darzynkiewicz Z., and Williams G.M. Assessment of DNA double-strand breaks and H2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutat. Res. 641 (2008) 43-47
114. Stawinska M., Cygankiewicz A., Trzcinski R., Mik M., Dziki A., and Krajewska W.M. Alterations of Chk1 and Chk2 expression in colon cancer. Int. J. Colorectal Dis. 23 (2008) 1243-1249
115. Stevens C., Smith L., and La Thangue N.B. Chk2 activates E2F-1 in response to DNA damage. Nat. Cell Biol. 5 (2003) 4465-4479
116. Stiff T.O., Driscoll M., Rief N., Iwabuchi K., Lobrich M., and Jeggo P.A. ATM and DNA-PK function redundantly to phosphorylated H2AX after exposure to ionizing radiation. Cancer Res. 64 (2004) 2390-2396
117. Stucki M., and Jackson S.P. MDC1/NFBD1: a key regulator of the DNA damage response in higher eukaryotes. DNA Repair (Amst.) 3 (2005) 953-957
118. Sun Y., Jiang X., Chen S., Fernandes N., and Price B.D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13182-13187
119. Syliuasen R.G., Sorensen C.S., Nylandsted J., Lukas C., Lukas J., and Bartek J. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation. Cancer Res. 64 (2004) 9035-9040
120. Tan Y., Raychaudhuri P., and Costa R.H. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol. Cell Biol. 27 (2007) 1007-1016
121. Tanaka T., Halicka H.D., Huang X., Traganos F., and Darzynkiewicz Z. Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle 5 (2006) 1940-1945
122. Tanaka T., Halicka H.D., Traganos F., Seiter K., and Darzynkiewicz Z. Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to the cell cycle phase. Cell Cycle 6 (2007) 371-376
123. Tanaka T., Huang X., Halicka H.D., Zhao H., Traganos F., Albino A.P., Dai W., and Darzynkiewicz Z. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A 71A (2007) 648-661
124. Tao Z.F., and Lin N.H. Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med. Chem. 6 (2006) 377-388
125. Tassone P., Martino M.T., Ventura M., Pietragalla A., Cuccinotto I., Calimeri T., Bulotta A., Neri P., Caraglia M., and Tagliaferri P. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol. Ther. 8 7 (2009) (Apr28 Electronic publication)
126. Wakeman T.P., Kim W.J., Callens S., Chu A., Brown K.D., and Xu B. The ATM-SMC1 pathway is essential for activation of chromium [VI]-induced S-phase checkpoint. Mutat. Res. 554 (2004) 241-251
127. Wang W., and Figg W.D. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biol. Ther. 7 (2008) 1004-1007
128. Wang H., Wang M., Wang H., Bocker W., and Illiakis G. Complex H2AX phosphorylation patterns by multiple kinases including ATM and DNA-PK in human cells exposed to ionizing radiation and treated with kinase inhibitors. J. Cell Phys. 202 (2005) 492-502
129. Wang Z., Kar S., and Carr B.I. Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies. Anticancer Agents Med. Chem. 8 (2008) 863-871
130. Ward I.M., Minn K., and Chen J. UV-induced ataxia-telangiectasia-mutated and Rad3-related (ATR) activation requires replication stress. J. Biol. Chem. 279 (2004) 9677-9680
131. Wynne P., Newton C., Ledermann J.A., Olaitan A., Mould T.A., and Hartley J.A. Enhanced repair of DNMA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-baded chemotherapy. Br. J. Cancer 97 (2007) 927-933
132. Xiao A., Li H., Schechter D., Ahn S.H., Fabrizio L.A., Erdjument-Bromage H., Ishibe-Murakami S., Wang B., Tempst P., Hofmann K., Patel D.J., Elledge S.J., and Allis C.D. WSTF regulates the H2A.X DNA damage response via novel tyrosine kinase activity. Nature 457 (2009) 57-62
133. Yang S., Kuo C., Bisi J.E., and Kim M.K. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCdsa/Chk2. Nat. Cell Biol. 4 (2002) 865-870
134. Yazdi P.T., Wang Y., Zhao S., Patel N., Lee E.Y., and Qin J. SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev. 16 (2002) 571-582
135. Yuan S.S., Lee S.E., Chen G., Song M., Tomlinson G.E., and Lee F.Y. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 59 (1999) 3547-3551
136. Zhao H., Tanaka T., Halicka H.D., Traganos F., Zarebski M., Dobrucki J., and Darzynkiewicz Z. Cytometric assessment of DNA damage by exogenous and endogenous oxidants reports the aging-related processes. Cytometry A 71A (2007) 905-914
137. Zhao H., Traganos F., and Darzynkiewicz Z. Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase. Cytometry A 73A (2008) 480-489
138. Zhao H., Traganos F., Dobrucki J., Wlodkowic D., and Darzynkiewicz Z. Induction of DNA damage response by the supravital probes of nucleic acids. Cytometry A 75A (2009) (April 15 2009 Electronic publication)
139. Zhou B.B., and Elledge S.J. The DNA response: putting checkpoints in perspective. Nature 408 (2000) 433-439
140. Ziv Y., Bielopolski D., Galanty Y., Lukas C., Taya Y., Schultz D.C., Lukas J., Bekker-Jensen S., Bartek J., and Shiloh Y. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. Nat. Cell Biol. 8 (2006) 870-876